-
52-week Open Label Safety-Tolerability Study
NCT07369154 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Texas: DeSoto, Richardson
-
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
NCT07459647 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Texas: Austin, DeSoto, Richardson
-
A Study of Brenipatide in Adult Participants With Schizophrenia
NCT07410507 ·
Phase: Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Texas: DeSoto, Fort Worth
-
A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
NCT07734493 ·
Phase: Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Texas: Richardson
-
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
NCT07615426 ·
Phase: Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Texas: Austin, Richardson
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
NCT07145918 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Texas: Austin, Richardson
-
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
NCT06540833 ·
Phase: Phase 2 ·
Ages: 55 Years and older ·
Sex: All (male and female)
· Texas: Cypress, San Antonio
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCT06887192 ·
Phase: Phase 2 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female)
· Texas: Austin, McKinney, Sugarland
-
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
NCT07191483 ·
Phase: Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Texas: Austin
-
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787 ·
Phase: Phase 3 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female)
· Texas: Austin, Dallas, DeSoto, El Paso
-
A Study to Evaluate the Effect of KarXT on Urological Safety
NCT07221877 ·
Phase: Phase 4 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Texas: Austin, DeSoto
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT07105111 ·
Phase: Phase 4 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Austin
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
NCT07288567 ·
Phase: Phase 3 ·
Ages: 13 Years to 17 Years ·
Sex: All (male and female)
· Texas: Garland, Houston, Spring
-
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
NCT07424404 ·
Phase: Phase 3 ·
Ages: 5 Years to 17 Years ·
Sex: All (male and female)
· Texas: Dallas, Garland, Houston, Plano
-
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
NCT07061288 ·
Phase: Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Texas: Austin
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
NCT06894212 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Texas: Austin, DeSoto, Houston, Richardson
-
Alternative Stimulation Mode and Location for Auditory Hallucination Neuromodulation Treatment
NCT02916810 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 50 Years ·
Sex: All (male and female)
· Texas: Houston
-
Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia
NCT07060066 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Texas: Houston
-
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
NCT06740383 ·
Phase: Not specified ·
Ages: 18 Years to 40 Years ·
Sex: All (male and female)
· Texas: Dallas
-
CLOZAPINE Response in Biotype-1
NCT04580134 ·
Phase: Phase 4 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Texas: Dallas
-
Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)
NCT05276050 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 22 Years to 65 Years ·
Sex: All (male and female)
· Texas: Houston
-
Comparing Antipsychotic Medications in LBD Over Time
NCT05590637 ·
Phase: Phase 4 ·
Ages: No age limits stated ·
Sex: All (male and female)
· Texas: San Antonio
-
Database Registry for Neural Network Biomarkers in Psychosis
NCT01409109 ·
Phase: Not specified ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Texas: Dallas
-
Deep Brain Stimulation for Psychosis
NCT06257056 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 22 Years to 70 Years ·
Sex: All (male and female)
· Texas: Dallas
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
NCT05025605 ·
Phase: Phase 1 ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· Texas: DeSoto
-
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
NCT07379827 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Austin, Dallas, Fort Worth, Houston
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
NCT03817502 ·
Phase: Phase 3 ·
Ages: 13 Years to 17 Years ·
Sex: All (male and female)
· Texas: The Woodlands
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
NCT06345963 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Texas: Houston
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 2)
NCT06961916 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Texas: Houston
-
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
NCT07101094 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: El Paso, Longview
-
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT06963034 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Texas: Austin, DeSoto, Houston
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
NCT07114874 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Texas: Austin, DeSoto, Houston
-
Ocrelizumab for Psychosis by Autoimmunity
NCT03971487 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 35 Years ·
Sex: All (male and female)
· Texas: Houston
-
Preventing Vulnerable Child Syndrome in the NICU With Cognitive Behavioral Therapy (PreVNT Trial)
NCT03906435 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: No age limits stated ·
Sex: All (male and female)
· Texas: Dallas
-
Randomized Clinical Trial of iTEST: A Blended Intervention Targeting Introspective Accuracy
NCT07098169 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Texas: Dallas
-
Randomized Withdrawal Study in Patients With Schizophrenia
NCT06961968 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Texas: Austin, Houston, Irving, Richardson
-
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
NCT07686263 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Texas: Austin, Dallas, Richardson
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
NCT05184335 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Texas: Austin, Richardson
-
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
NCT06229210 ·
Phase: Phase 3 ·
Ages: 5 Years to 17 Years ·
Sex: All (male and female)
· Texas: Coppell, Fort Worth, Houston, Plano
-
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
NCT07565428 ·
Phase: Phase 3 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Texas: Richardson
-
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT05303064 ·
Phase: Phase 3 ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· Texas: DeSoto, Fort Worth
-
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
NCT07680946 ·
Phase: Phase 2 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Texas: Richardson
-
The Effectiveness of Individualized Imagery Scripts on Sleep, Psychosis, and Suicidality Among Inpatients With Psychosis
NCT06194344 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
Transcranial Magnetic Stimulation (TMS) for Negative Symptoms in Schizophrenia Spectrum Disorders
NCT07290738 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Texas: Houston